Exploring the benefits, harms and costs of genomic newborn screening for rare diseases

The prospect of genomic screening in newborns attracts both hype and criticism, but carefully designed, large-scale, prospective research studies are the only way to generate the data needed for its rigorous evaluation.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature medicine 2024-07, Vol.30 (7), p.1823-1825
Hauptverfasser:	Baple, Emma L., Scott, Richard H., Banka, Siddharth, Buchanan, James, Fish, Louise, Wynn, Sarah, Wilkinson, Dominic, Ellard, Sian, MacArthur, Daniel G., Stark, Zornitza
Format:	Artikel
Sprache:	eng
Schlagworte:	692/308/2056 692/700/1538 Anemia Biomedical and Life Sciences Biomedicine Cancer Research Comment Costs Ethics Genomics Health technology assessment Infectious Diseases Medical screening Metabolic Diseases Molecular Medicine Neonates Neurosciences Public health Rare diseases T cell receptors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The prospect of genomic screening in newborns attracts both hype and criticism, but carefully designed, large-scale, prospective research studies are the only way to generate the data needed for its rigorous evaluation.
ISSN:	1078-8956 1546-170X 1546-170X
DOI:	10.1038/s41591-024-03055-x